PVRIG

Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024

Retrieved on: 
Wednesday, March 6, 2024

HOLON, Israel, March 6, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it will present data from its differentiated immuno-oncology preclinical and clinical pipeline, in two poster presentations at the American Association for Cancer Research (AACR) annual meeting on April 5-11, 2024, in San Diego, California.

Key Points: 
  • HOLON, Israel, March 6, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it will present data from its differentiated immuno-oncology preclinical and clinical pipeline, in two poster presentations at the American Association for Cancer Research (AACR) annual meeting on April 5-11, 2024, in San Diego, California.
  • "It is exciting that the progress we have made to potentially address immunotherapy resistance from diverse angles will be reflected at AACR this year," said Anat Cohen-Dayag, Ph.D., President, and CEO of Compugen.
  • Eran Ophir, Ph.D., Chief Scientific Officer at Compugen, added, "At ACCR we will present data supporting the unique biology of PVRIG suggesting its role in sensitizing tumors to other immune checkpoints TIGIT and PD-(L)1.
  • The data will be published in the online Proceedings supplement to the AACR journal Cancer Research prior to the meeting on Friday, March 22, 2024.

Compugen's COM701 (anti-PVRIG) Mediates Anti-Tumor Activity in Patients Typically Not Responding to Immunotherapy

Retrieved on: 
Monday, November 6, 2023

The results reinforce previous data suggesting COM701 mediated anti-tumor activity in patients typically not responding to immunotherapy.

Key Points: 
  • The results reinforce previous data suggesting COM701 mediated anti-tumor activity in patients typically not responding to immunotherapy.
  • "We were delighted to present at SITC clinical data which reinforces data previously presented, suggesting that COM701 mediated anti-tumor activity in patients typically not responding to immunotherapy", said Anat Cohen-Dayag, Ph.D., President, and CEO of Compugen.
  • In addition, we presented data in metastatic breast cancer, another indication in which patients who typically do not respond to immunotherapy, derived clinical benefit from COM701 combinations."
  • I look forward to the results of the ongoing proof-of-concept study evaluating the combination of COM701, COM902 and pembrolizumab in platinum resistant ovarian cancer patients."

Compugen to Present at Single Cell Genomics 2023 Meeting

Retrieved on: 
Tuesday, October 3, 2023

HOLON, Israel, Oct. 3, 2023 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, it will present innovative single-cell approaches and high resolution single cell spatial transcriptomics data at the Single Cell Genomics 2023 meeting taking place between 9-11 October 2023, Engelberg, Switzerland.

Key Points: 
  • HOLON, Israel, Oct. 3, 2023 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, it will present innovative single-cell approaches and high resolution single cell spatial transcriptomics data at the Single Cell Genomics 2023 meeting taking place between 9-11 October 2023, Engelberg, Switzerland.
  • The data will highlight the computational characterization of PVRIG's expression providing a deeper understanding of its unique biology and rationale for targeting PVRIG in tumors, typically those not responding to immunotherapy.
  • Poster Title: Elucidating the Mechanism of Action of the Novel Immune Checkpoint PVRIG: Insights from Single-Cell and High-Resolution Spatial Transcriptomics
    The poster will be available on the publications section of Compugen's website, www.cgen.com , following presentation.

Compugen Expands Intellectual Property with New Japanese Patent for the Triple Combination of any Anti-PVRIG, TIGIT and PD-1 Antibody for the Treatment of Cancer

Retrieved on: 
Monday, October 2, 2023

HOLON, Israel, Oct. 2,  2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Japanese Patent Office has granted Compugen a patent for treating cancer with a triple combination of any anti- PVRIG antibody with any anti-TIGIT and anti-PD-1 antibody.

Key Points: 
  • HOLON, Israel, Oct. 2,  2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Japanese Patent Office has granted Compugen a patent for treating cancer with a triple combination of any anti- PVRIG antibody with any anti-TIGIT and anti-PD-1 antibody.
  • Japanese patent No.
  • JP7348072B2 , titled "Triple Combination Antibodies Therapies" augments previously issued patent in Japan by expanding and protecting Compugen's differentiated and leading triple blockade of the DNAM-1 axis with any anti-PVRIG in combination with any anti-TIGIT and anti-PD-1 antibody.
  • "We are delighted to strengthen our patent portfolio supporting our leadership in blocking three pathways of the DNAM-1 axis, PVRIG, TIGIT and PD-1", said Anat Cohen-Dayag, Ph.D., President, and Chief Executive Officer of Compugen.

Compugen Wins on PVRIG European Patent Opposition Pursued by GSK and a Third Party

Retrieved on: 
Monday, July 17, 2023

Oppositions were pursued by GSK and an anonymous opponent represented by a third party against EP3258951B1 .

Key Points: 
  • Oppositions were pursued by GSK and an anonymous opponent represented by a third party against EP3258951B1 .
  • In an oral proceedings hearing on July 11 2023, the opposition division of the European Patent Office ruled in favor of maintaining the broad claims in the patent as granted to Compugen.
  • "We are delighted with the decision of the opposition division of the European Patent Office ruling in favor of maintenance of the broad claims in the patent as granted, supporting our patent strategy in novel target discovery."
  • Compugen was represented by Markus Rieck, LL.M., Partner, Patent Attorney, Fuchs Patentanwälte Partnerschaft mbB and Thomas Wolter, Partner, Patent Attorney, Mewburn Ellis LLP.

Compugen Reports First Quarter 2023 Results

Retrieved on: 
Monday, May 15, 2023

R&D expenses for the first quarter of 2023, were approximately $7.4 million compared with approximately $7.2 million for the comparable period in 2022.

Key Points: 
  • R&D expenses for the first quarter of 2023, were approximately $7.4 million compared with approximately $7.2 million for the comparable period in 2022.
  • General and administrative expenses for the first quarter of 2023, were approximately $2.6 million, compared with approximately $2.6 million for the comparable period in 2022.
  • Net loss for the first quarter of 2023, was approximately $9.3 million, or $0.11 per basic and diluted share, compared with a net loss of approximately $9.7 million, or $0.11 per basic and diluted share, in the first quarter of 2022.
  • The Company will hold a conference call today, May 15, 2023, at 8:30 AM ET to review its first quarter 2023 results.

Compugen to Host DNAM-1 Axis Virtual Investor Event with KOL Drew Pardoll on Tuesday, May 23, 2023

Retrieved on: 
Thursday, May 11, 2023

HOLON, Israel, May 11, 2023 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will host a virtual DNAM-1 Axis Investor Event on Tuesday, May 23, 2023 at 12:00 pm ET.

Key Points: 
  • HOLON, Israel, May 11, 2023 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will host a virtual DNAM-1 Axis Investor Event on Tuesday, May 23, 2023 at 12:00 pm ET.
  • A short introductory presentation will be provided by Compugen's SVP Research and Drug Discovery, Eran Ophir, Ph.D., followed by a discussant presentation by Dr. Pardoll.
  • A live question and answer session with Dr. Pardoll and members of Compugen's leadership team will follow the formal presentations.
  • To register for the event, please click here .

Biosion bispecific antibody therapies to be featured at the American Association for Cancer Research (AACR) annual meeting 2023

Retrieved on: 
Wednesday, March 22, 2023

NEWARK, Del., March 22, 2023 /PRNewswire/ -- Biosion USA, Inc. (Biosion), a global R&D biotechnology company, today announced the upcoming presentations of non-clinical data from its oncology pipeline, including BSI-507: anti-PD1ⅹanti-PVRIG bispecific antibody and BSI-508: anti-PD1ⅹanti-CD47 bispecific antibody, at the American Association for Cancer Research (AACR) Annual Meeting to be held from April 14 to 19, 2023.

Key Points: 
  • NEWARK, Del., March 22, 2023 /PRNewswire/ -- Biosion USA, Inc. (Biosion), a global R&D biotechnology company, today announced the upcoming presentations of non-clinical data from its oncology pipeline, including BSI-507: anti-PD1ⅹanti-PVRIG bispecific antibody and BSI-508: anti-PD1ⅹanti-CD47 bispecific antibody, at the American Association for Cancer Research (AACR) Annual Meeting to be held from April 14 to 19, 2023.
  • BSI-507, a first-in-class anti-PD1ⅹanti-PVRIG bispecific antibody, discovered through Biosion's H³ antibody discovery platform, is able to block both PD-1 and PVRIG pathways to enhance reversal of T cell inhibition.
  • BSI-507 demonstrates favorable biophysical and functional characteristics, supporting the initiation of development activities including manufacturing and IND-enabling studies.
  • BSI-508 is a novel anti-PD1ⅹanti-CD47 bispecific fusion molecule combining both T-cell activation and macrophage mediated phagocytosis together for superior tumor killing.

Zentalis Pharmaceuticals Appoints Dr. Iris Roth as Chief Operating Officer

Retrieved on: 
Monday, February 13, 2023

NEW YORK and SAN DIEGO, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Iris Roth, PhD, as Chief Operating Officer (COO).

Key Points: 
  • NEW YORK and SAN DIEGO, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Iris Roth, PhD, as Chief Operating Officer (COO).
  • Dr. Roth joins Zentalis with over two decades of biopharmaceutical experience building and executing clinical and operational strategies, successfully advancing the development of multiple investigational therapies in oncology.
  • “I am incredibly pleased to welcome Iris to Zentalis, rounding out our management team with a seasoned leader who has extensive experience in oncology drug development,” said Dr. Kimberly Blackwell, Chief Executive Officer of Zentalis.
  • Prior to GSK, Dr. Roth served in senior leadership roles at various biopharmaceutical companies, including as Chief Operating Officer of Kartos Therapeutics, and Vice President, Global Medicine Leader of AstraZeneca.

TG ImmunoPharma (TGI) announces FDA clearance of IND application for TGI-2, a novel anti-PVRIG therapeutic antibody

Retrieved on: 
Saturday, December 17, 2022

TGI-2/NM1F is a humanized IgG1 monoclonal antibody targeting PVRIG for the treatment of malignant cancers.

Key Points: 
  • TGI-2/NM1F is a humanized IgG1 monoclonal antibody targeting PVRIG for the treatment of malignant cancers.
  • The antibody binds to PVRIG with high affinity to block the PVRIG/PVRL2 interaction and restore the antitumor immune functions of both NK cells and T cells.
  • Preclinical data suggest that TGI-2/NM1F has a long half-life and is well tolerated at very high doses in nonhuman primates.
  • "It is a significant milestone for TGI, having received clearance from the FDA to advance TGI-2 into the clinical trials.